about
Biology-driven cancer drug development: back to the futureFrom Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and BeyondThe impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industries. Part XXX: Causal relationship between chronic myelogenous leukemia and benzene-containing solvents.Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.Deactylase inhibition in myeloproliferative neoplasms.Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Chronic myeloid leukemia: past, present, future.Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology.Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia.Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East.Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemiaEpigenetic regulation of HOTAIR in advanced chronic myeloid leukemia
P2860
Q33552888-037F536C-4A81-4417-88B9-25B0D9CE6FFEQ34972855-B37883B7-A8E5-4BBF-9D8D-B6F82D85BA0FQ36309977-7CD007BF-4C98-42FA-960F-06953731B2C7Q36392598-8AE19C00-0A3C-4396-9A39-DB0AB026F868Q36660033-F2CDC4BC-18E6-4DD8-B2FE-EB50A68463A4Q37810070-83DD6FF7-0A46-423F-A503-FF033B814F2DQ37815421-B0B2D2FE-9DC7-4F8D-9F7A-160C77A9AAEFQ37866150-969453A1-87A3-4D62-99C5-09DEA1A7AE94Q38694690-1C83E475-57C3-46D4-B6A9-58ACB22A76A5Q40650613-F99C850D-85BE-44D4-A6F0-47660CE16C85Q41892316-56E920E6-B8A2-4A3C-9D8E-7B45991A13E1Q42367946-18979E5E-F731-4B1C-BF76-27360531F677Q46447882-82CF7997-039E-49B5-86C7-0DC51574AEDBQ53833882-59295510-0D34-4377-B9F3-F19A9B4A413BQ54950945-6581F2D8-F980-41CB-8E49-B032DDFC25E7Q56794302-A08E1B7E-2451-4444-8AEE-C6EF05FAD1BBQ59135040-27309648-3E2D-4EE7-A6C4-22281CCDD0BD
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The story of chronic myeloid leukaemia.
@en
The story of chronic myeloid leukaemia.
@nl
type
label
The story of chronic myeloid leukaemia.
@en
The story of chronic myeloid leukaemia.
@nl
prefLabel
The story of chronic myeloid leukaemia.
@en
The story of chronic myeloid leukaemia.
@nl
P2860
P1476
The story of chronic myeloid leukaemia.
@en
P2093
P2860
P356
10.1046/J.1365-2141.2000.02137.X
P407
P577
2000-07-01T00:00:00Z